PP
CLDI icon

Pegasus Partners’s Calidi Biotherapeutics CLDI Stock Holding History

Pegasus Partners’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-458
Closed -$31.1K – 168
2024
Q1 		$31.1K Buy
458
+143
+45% +$14.6K ﹤0.01% 149
2023
Q4 		$57.1K Buy
+315
New +$84.5K 0.01% 142

Other funds holding CLDI

RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Pegasus Partners's CLDI Position: Q2 2024 in Review

Pegasus Partners sold out of Calidi Biotherapeutics (CLDI) in Q2 2024, closing a stake of 458 shares — an estimated $31.1K sold.

Pegasus Partners first reported a position in CLDI in Q4 2023 and held it in 2 quarters. The position peaked at $57.1K in Q4 2023. 31 funds tracked by Wall St. Rank hold CLDI as of Q2 2024.

  • Pegasus Partners reported no remaining Calidi Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Pegasus Partners sold 458 Calidi Biotherapeutics shares in Q2 2024, an estimated $31.1K.
  • Pegasus Partners first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Pegasus Partners's Calidi Biotherapeutics position peaked at $57.1K in Q4 2023.
  • 31 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2024.

Based on Pegasus Partners's 13F filing for Q2 2024, filed 8 Aug 2024.